董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Howard Chen | 男 | Chairman of the Board, Director, Chief Executive Officer | -- | 未披露 | 未持股 | 2025-11-16 |
| Chen, Hong Jung | 男 | Independent Director | 65 | 未披露 | 0.47 | 2025-11-16 |
| Yi Kuei Chen | 男 | Director, Chief Operating Officer | -- | 未披露 | 未持股 | 2025-11-16 |
| Hsien Chu Tsai | 男 | Independent Director | -- | 未披露 | 未持股 | 2025-11-16 |
| Yi An Chu | 男 | Independent Director | -- | 未披露 | 未持股 | 2025-11-16 |
| Chen Huan Jan | 男 | Independent Director | -- | 未披露 | 未持股 | 2025-11-16 |
| Ya Chi Huang | 女 | Independent Director | -- | 未披露 | 未持股 | 2025-11-16 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Howard Chen | 男 | Chairman of the Board, Director, Chief Executive Officer | -- | 未披露 | 未持股 | 2025-11-16 |
| Peter Lin | 男 | Chief Financial Officer | -- | 未披露 | 未持股 | 2025-11-16 |
| Yi Kuei Chen | 男 | Director, Chief Operating Officer | -- | 未披露 | 未持股 | 2025-11-16 |
董事简历
中英对照 | 中文 | 英文- Howard Chen
-
Howard Chen，是Gemtek科技有限公司的创始人和董事长，也是Polaris Pharmaceuticals，Inc.的前董事长兼首席执行官，目前担任Polaris执行董事。Mr. Chen拥有台湾国立清华大学物理学学士及电子工程硕士学位。他的职业生涯始于台积电（TSMC），从事半导体工艺和集成电路的研发工作。后来他创立了Gemtek科技，该公司自此成长为全球领先的专业无线宽带设备制造商之一，在国际市场拥有强大的影响力。为表彰他对科技行业的贡献，Mr. Chen于2010年获得国立清华大学杰出校友奖，并于2013年获得ERSO奖，这是台湾科技领域最负盛名的荣誉之一。2019年，北极星制药面临严重的财务危机，因为其许多临床试验仍不确定，同时成本和费用超出了公司的能力。在这段困难时期，Mr. Chen介入，果断出手，稳住了公司。在他的领导下，北极星进行了全面的战略重组，在他的管理团队的努力下，公司实现了令人瞩目的扭亏为盈，最终于2022年6月在台湾成功IPO。
Howard Chen,is the Founder and Chairman of Gemtek Technology Co., Ltd. and the Former Chairman and CEO of Polaris Pharmaceuticals, Inc., and currently serving as an Executive Director of Polaris.Mr. Chen holds a Bachelor of Physics and a Master of Electronics Engineering from National Tsing Hua University, Taiwan. He began his career at Taiwan Semiconductor Manufacturing Company (TSMC), where he was engaged in research and development of semiconductor processes and integrated circuits.He later founded Gemtek Technology, which has since grown into one of the world's leading manufacturers of professional wireless broadband equipment, with a strong presence in international markets. In recognition of his contributions to the technology industry, Mr. Chen received the Outstanding Alumni Award from National Tsing Hua University in 2010 and was honored with the ERSO Award in 2013, one of the most prestigious accolades in Taiwan's technology sector.In 2019, Polaris Pharmaceuticals faced a severe financial crisis, as many of its clinical trials remained uncertain while costs and expenses exceeded the company's capacity. During this difficult period, Mr. Chen stepped in and took decisive action to stabilize the company. Under his leadership, Polaris underwent a comprehensive strategic reorganization, and with the efforts of his management team, the company achieved a remarkable turnaround, culminating in a successful IPO in Taiwan in June 2022. - Howard Chen，是Gemtek科技有限公司的创始人和董事长，也是Polaris Pharmaceuticals，Inc.的前董事长兼首席执行官，目前担任Polaris执行董事。Mr. Chen拥有台湾国立清华大学物理学学士及电子工程硕士学位。他的职业生涯始于台积电（TSMC），从事半导体工艺和集成电路的研发工作。后来他创立了Gemtek科技，该公司自此成长为全球领先的专业无线宽带设备制造商之一，在国际市场拥有强大的影响力。为表彰他对科技行业的贡献，Mr. Chen于2010年获得国立清华大学杰出校友奖，并于2013年获得ERSO奖，这是台湾科技领域最负盛名的荣誉之一。2019年，北极星制药面临严重的财务危机，因为其许多临床试验仍不确定，同时成本和费用超出了公司的能力。在这段困难时期，Mr. Chen介入，果断出手，稳住了公司。在他的领导下，北极星进行了全面的战略重组，在他的管理团队的努力下，公司实现了令人瞩目的扭亏为盈，最终于2022年6月在台湾成功IPO。
- Howard Chen,is the Founder and Chairman of Gemtek Technology Co., Ltd. and the Former Chairman and CEO of Polaris Pharmaceuticals, Inc., and currently serving as an Executive Director of Polaris.Mr. Chen holds a Bachelor of Physics and a Master of Electronics Engineering from National Tsing Hua University, Taiwan. He began his career at Taiwan Semiconductor Manufacturing Company (TSMC), where he was engaged in research and development of semiconductor processes and integrated circuits.He later founded Gemtek Technology, which has since grown into one of the world's leading manufacturers of professional wireless broadband equipment, with a strong presence in international markets. In recognition of his contributions to the technology industry, Mr. Chen received the Outstanding Alumni Award from National Tsing Hua University in 2010 and was honored with the ERSO Award in 2013, one of the most prestigious accolades in Taiwan's technology sector.In 2019, Polaris Pharmaceuticals faced a severe financial crisis, as many of its clinical trials remained uncertain while costs and expenses exceeded the company's capacity. During this difficult period, Mr. Chen stepped in and took decisive action to stabilize the company. Under his leadership, Polaris underwent a comprehensive strategic reorganization, and with the efforts of his management team, the company achieved a remarkable turnaround, culminating in a successful IPO in Taiwan in June 2022.
- Chen, Hong Jung
-
Chen, Hong Jung担任Apollomics Inc.董事会成员。陈博士自2018年5月起担任Maxpro Ventures LTD的董事总经理，Maxpro Ventures LTD是一家专注于突破性生物医学技术公司的投资公司，曾担任Maxpro的董事会主席和首席执行官。此前，2014年10月至2017年1月，陈博士在台湾SyneuRX International Corp.担任副总裁兼代理首席运营官，负责监督公司的日常运营，并亲自与VC代表和私人投资者互动。陈博士在制定和实施小分子、生物制剂和细胞治疗的基础研究和临床前开发战略方面拥有20多年的经验，在推进候选药物从发现到提名IND和开发方面也很有经验。陈博士在罗格斯大学、新泽西州立大学和新泽西医学与牙科大学获得微生物学和分子遗传学博士学位。他在加州理工学院完成了神经科学的博士后培训。
Chen, Hong Jung,serves as a member of board of directors. Dr. Chen was Managing Director of Maxpro Ventures LTD from May 2018 to February 2024, which is an investment firm focused on breakthrough biomedical technology companies, and served as Chairman of the Board of Directors and Chief Executive Officer of Maxpro Capital Acquisition Corp. from June 2021 to March 2023. Dr. Chen is also an ad hoc reviewer of Stem Cells Translational Medicine, and has served as director of Uneuron Biomedical Co. Ltd. since March 2023, and has been a supervisor of ReVasgen Inc. since October 2014. Previously, from October 2014 to January 2017, Dr. Chen worked as Vice President and Acting Chief Operating Officer for SyneuRx International Corp. in Taiwan, where he was responsible for supervising the company's daily operation and personally interacting with VC representatives and private investors. Dr. Chen has more than 20 years of experience in formulating and implementing basic research and preclinical development strategies for small molecules, biologics and cell therapy and is also experienced in advancing drug candidates from discovery to nomination for IND and development. Dr. Chen received his Ph.D. in Microbiology and Molecular Genetics from Rutgers, The State University of New Jersey and The University of Medicine and Dentistry of New Jersey. He completed his postdoctoral training in neuroscience at California Institute of Technology. - Chen, Hong Jung担任Apollomics Inc.董事会成员。陈博士自2018年5月起担任Maxpro Ventures LTD的董事总经理，Maxpro Ventures LTD是一家专注于突破性生物医学技术公司的投资公司，曾担任Maxpro的董事会主席和首席执行官。此前，2014年10月至2017年1月，陈博士在台湾SyneuRX International Corp.担任副总裁兼代理首席运营官，负责监督公司的日常运营，并亲自与VC代表和私人投资者互动。陈博士在制定和实施小分子、生物制剂和细胞治疗的基础研究和临床前开发战略方面拥有20多年的经验，在推进候选药物从发现到提名IND和开发方面也很有经验。陈博士在罗格斯大学、新泽西州立大学和新泽西医学与牙科大学获得微生物学和分子遗传学博士学位。他在加州理工学院完成了神经科学的博士后培训。
- Chen, Hong Jung,serves as a member of board of directors. Dr. Chen was Managing Director of Maxpro Ventures LTD from May 2018 to February 2024, which is an investment firm focused on breakthrough biomedical technology companies, and served as Chairman of the Board of Directors and Chief Executive Officer of Maxpro Capital Acquisition Corp. from June 2021 to March 2023. Dr. Chen is also an ad hoc reviewer of Stem Cells Translational Medicine, and has served as director of Uneuron Biomedical Co. Ltd. since March 2023, and has been a supervisor of ReVasgen Inc. since October 2014. Previously, from October 2014 to January 2017, Dr. Chen worked as Vice President and Acting Chief Operating Officer for SyneuRx International Corp. in Taiwan, where he was responsible for supervising the company's daily operation and personally interacting with VC representatives and private investors. Dr. Chen has more than 20 years of experience in formulating and implementing basic research and preclinical development strategies for small molecules, biologics and cell therapy and is also experienced in advancing drug candidates from discovery to nomination for IND and development. Dr. Chen received his Ph.D. in Microbiology and Molecular Genetics from Rutgers, The State University of New Jersey and The University of Medicine and Dentistry of New Jersey. He completed his postdoctoral training in neuroscience at California Institute of Technology.
- Yi Kuei Chen
-
Yi Kuei Chen，生物技术和风险投资背景，是Maxpro Ventures的联合创始人。Mr. Chen在资产管理方面的专业知识使他在美国和亚太地区成功执行了60多项私募股权投资交易。他过去的投资包括Acepodia、Syneurx、金斯瑞、JHL Biotech、Foresee、HEC Pharma和ACT Genomics Holdings等。在共同创立Maxpro Ventures之前，Mr. Chen是Integral Group的高级董事。他曾共同负责Integral的亚洲交易流程，管理其上海分公司，并担任过Generon Corporation、FusionVax，Inc.、BioLite，Inc.、Flora International Group Co.，Ltd.等多家投资组合公司的董事会成员。1999年至2012年，Mr. Chen曾在中环投资控股的投资部门担任多个高级管理职务。在此期间，他的成功投资包括Tanox和Biopure，仅举几例。2002年，Mr. Chen做过的一笔重大交易，就是新世纪信通科技收购SEEDNet。他还曾在多个公司董事会任职，如Concord Fund Company、Singfor Life Insurance Company、CTCI Corporation。Mr. Chen获得了雪城大学的MBA学位和明尼苏达大学的硕士学位。
Yi Kuei Chen,with backgrounds in biotechnology and venture capital, is a co-founder of Maxpro Ventures. Mr. Chen's professional expertise in asset management has led to his successful execution of more than 60 private equity investment transactions in the USA and the Asia-Pacific region. His past investments include Acepodia, SyneuRx, GenScript, JHL Biotech, Foresee, HEC Pharma, and ACT Genomics Holdings, amongst others.Prior to co-founding Maxpro Ventures, Mr. Chen was the Senior Director of Integral Group. He was jointly in charge of Integral's Asian transaction process, managed its Shanghai branch, and served as a board member of multiple portfolio companies such as Generon Corporation, FusionVax, Inc., BioLite, Inc., and Flora International Group Co., Ltd.. From 1999 to 2012, Mr. Chen held various senior management positions in the investment division at Central Investment Holdings. During that period, his successful investments included Tanox and Biopure, to name just a few. In 2002, a significant transaction that Mr. Chen had made was the acquisition of SEEDNet by New Century InfoComm Tech. He also served on several corporate boards, such as Concord Fund Company, Singfor Life Insurance Company, and CTCI Corporation.Mr. Chen received an MBA from Syracuse University and an MS from the University of Minnesota. - Yi Kuei Chen，生物技术和风险投资背景，是Maxpro Ventures的联合创始人。Mr. Chen在资产管理方面的专业知识使他在美国和亚太地区成功执行了60多项私募股权投资交易。他过去的投资包括Acepodia、Syneurx、金斯瑞、JHL Biotech、Foresee、HEC Pharma和ACT Genomics Holdings等。在共同创立Maxpro Ventures之前，Mr. Chen是Integral Group的高级董事。他曾共同负责Integral的亚洲交易流程，管理其上海分公司，并担任过Generon Corporation、FusionVax，Inc.、BioLite，Inc.、Flora International Group Co.，Ltd.等多家投资组合公司的董事会成员。1999年至2012年，Mr. Chen曾在中环投资控股的投资部门担任多个高级管理职务。在此期间，他的成功投资包括Tanox和Biopure，仅举几例。2002年，Mr. Chen做过的一笔重大交易，就是新世纪信通科技收购SEEDNet。他还曾在多个公司董事会任职，如Concord Fund Company、Singfor Life Insurance Company、CTCI Corporation。Mr. Chen获得了雪城大学的MBA学位和明尼苏达大学的硕士学位。
- Yi Kuei Chen,with backgrounds in biotechnology and venture capital, is a co-founder of Maxpro Ventures. Mr. Chen's professional expertise in asset management has led to his successful execution of more than 60 private equity investment transactions in the USA and the Asia-Pacific region. His past investments include Acepodia, SyneuRx, GenScript, JHL Biotech, Foresee, HEC Pharma, and ACT Genomics Holdings, amongst others.Prior to co-founding Maxpro Ventures, Mr. Chen was the Senior Director of Integral Group. He was jointly in charge of Integral's Asian transaction process, managed its Shanghai branch, and served as a board member of multiple portfolio companies such as Generon Corporation, FusionVax, Inc., BioLite, Inc., and Flora International Group Co., Ltd.. From 1999 to 2012, Mr. Chen held various senior management positions in the investment division at Central Investment Holdings. During that period, his successful investments included Tanox and Biopure, to name just a few. In 2002, a significant transaction that Mr. Chen had made was the acquisition of SEEDNet by New Century InfoComm Tech. He also served on several corporate boards, such as Concord Fund Company, Singfor Life Insurance Company, and CTCI Corporation.Mr. Chen received an MBA from Syracuse University and an MS from the University of Minnesota.
- Hsien Chu Tsai
-
Hsien Chu Tsai，是一位积累了20多年跨行业专长跨越投资、业务重组、财务管理的专业人士，在创业投资、企业融资、战略管理等方面具有丰富经验。Mr. Tsai曾在主要企业集团和创新机构担任领导职务，包括鸿海集团、顶新国际集团和信息产业研究院（III）。他的职业生涯反映了在资本市场运营、行业分析和金融战略执行方面的良好业绩记录，既支持老牌企业，也支持新兴企业。在最近担任III战略顾问之前，Mr. Tsai曾在顶新集团担任战略投资主管，并在那里领导企业投资战略、新企业孵化和跨境联盟。他在与研华、顺丰成立浆果咖啡、新乡云、物流科技合资公司等新企业中发挥了举足轻重的作用。在其职业生涯的早期，他曾在江西阳光能和苏州和骏新能源担任CFO的高级财务领导职务，在那里他领导了融资、IPO准备和公司重组计划。Mr. Tsai在鸿海集团旗下的鸿洋创投开始了他的投资生涯，在那里他管理着多个行业的私募股权交易和投资组合公司。他还以III级投资经理的身份为台湾的数字经济倡议做出了贡献，支持处于早期阶段的公司进行融资和战略增长。Mr. Tsai拥有肯特州立大学金融学MBA学位和国立中兴大学会计学工商管理学士学位。
Hsien Chu Tsai,is a professional has accumulated more than 20 years of cross-industry expertise spanning investment, business restructuring, and financial management, with extensive experience in venture capital, corporate finance, and strategic management. Mr. Tsai has held leadership roles across major conglomerates and innovation institutions, including Hon Hai Group, Ting Hsin International Group, and the Institute for Information Industry (III). His career reflects a strong track record in capital market operations, industry analysis, and financial strategy execution, supporting both established enterprises and emerging ventures.Prior to his most recent role as Strategic Advisor at III, Mr. Tsai served as Head of Strategic Investment at Ting Hsin Group, where he spearheaded corporate investment strategies, new business incubation, and cross-border alliances. He played a pivotal role in establishing new ventures such as Berry Coffee, Xinxiang Cloud, and logistics-tech joint ventures with Advantech and SF Express. Earlier in his career, he held senior finance leadership positions as CFO at Jiangxi Sunergy and Suzhou Hejun New Energy, where he led capital raising, IPO preparation, and corporate restructuring initiatives.Mr. Tsai began his investment career at Hung Yang Venture Capital, a subsidiary of Hon Hai Group, where he managed private equity transactions and portfolio companies across multiple industries. He also contributed to Taiwan's digital economy initiatives as an Investment Manager at III, supporting early-stage companies in financing and strategic growth.Mr. Tsai holds an MBA in Finance from Kent State University and a Bachelor of Business Administration in Accounting from National Chung Hsing University. - Hsien Chu Tsai，是一位积累了20多年跨行业专长跨越投资、业务重组、财务管理的专业人士，在创业投资、企业融资、战略管理等方面具有丰富经验。Mr. Tsai曾在主要企业集团和创新机构担任领导职务，包括鸿海集团、顶新国际集团和信息产业研究院（III）。他的职业生涯反映了在资本市场运营、行业分析和金融战略执行方面的良好业绩记录，既支持老牌企业，也支持新兴企业。在最近担任III战略顾问之前，Mr. Tsai曾在顶新集团担任战略投资主管，并在那里领导企业投资战略、新企业孵化和跨境联盟。他在与研华、顺丰成立浆果咖啡、新乡云、物流科技合资公司等新企业中发挥了举足轻重的作用。在其职业生涯的早期，他曾在江西阳光能和苏州和骏新能源担任CFO的高级财务领导职务，在那里他领导了融资、IPO准备和公司重组计划。Mr. Tsai在鸿海集团旗下的鸿洋创投开始了他的投资生涯，在那里他管理着多个行业的私募股权交易和投资组合公司。他还以III级投资经理的身份为台湾的数字经济倡议做出了贡献，支持处于早期阶段的公司进行融资和战略增长。Mr. Tsai拥有肯特州立大学金融学MBA学位和国立中兴大学会计学工商管理学士学位。
- Hsien Chu Tsai,is a professional has accumulated more than 20 years of cross-industry expertise spanning investment, business restructuring, and financial management, with extensive experience in venture capital, corporate finance, and strategic management. Mr. Tsai has held leadership roles across major conglomerates and innovation institutions, including Hon Hai Group, Ting Hsin International Group, and the Institute for Information Industry (III). His career reflects a strong track record in capital market operations, industry analysis, and financial strategy execution, supporting both established enterprises and emerging ventures.Prior to his most recent role as Strategic Advisor at III, Mr. Tsai served as Head of Strategic Investment at Ting Hsin Group, where he spearheaded corporate investment strategies, new business incubation, and cross-border alliances. He played a pivotal role in establishing new ventures such as Berry Coffee, Xinxiang Cloud, and logistics-tech joint ventures with Advantech and SF Express. Earlier in his career, he held senior finance leadership positions as CFO at Jiangxi Sunergy and Suzhou Hejun New Energy, where he led capital raising, IPO preparation, and corporate restructuring initiatives.Mr. Tsai began his investment career at Hung Yang Venture Capital, a subsidiary of Hon Hai Group, where he managed private equity transactions and portfolio companies across multiple industries. He also contributed to Taiwan's digital economy initiatives as an Investment Manager at III, supporting early-stage companies in financing and strategic growth.Mr. Tsai holds an MBA in Finance from Kent State University and a Bachelor of Business Administration in Accounting from National Chung Hsing University.
- Yi An Chu
-
Yi An Chu，拥有广泛的金融、投资、科技背景，30多年专业经验横跨资本市场和高科技行业。他是Global Investment Holdings（股票代码：3701）的前任首席财务官，此前曾在几大企业集团担任高级领导职务，包括仁宝、威盛科技和富士康。他的专业专长涵盖企业融资、投资管理、战略规划和业务运营，在领导投资项目和企业重组举措方面拥有良好的业绩记录。Mr. Chu也曾担任过Go TrustID、Gorilla Technology、酵母科技、协鑫半导（后并入WIN Semiconductors）等多家上市公司的董事会董事或代表。他的公司治理经验凸显了他将财务战略与运营执行联系起来的能力，指导公司度过关键的增长和转型阶段。在担任CFO职务之前，Mr. Chu曾担任宽宝科技副总裁（代理总经理）、通宝光电投资总监、仁宝电子高级经理。在其职业生涯早期，他曾在威盛科技担任投资总监，在富士康PCB部门担任助理副总裁，在资本证券担任高级电子研究分析师。Mr. Chu在纽约市立大学巴鲁克学院获得金融与投资MBA学位，在国立交通大学获得电气工程学士学位。他独特地融合了工程背景和金融敏锐度，这使他能够驾驭投资和企业管理的技术和战略层面。
Yi An Chu,with extensive backgrounds in finance, investment, and technology, has over 30 years of professional experience spanning the capital markets and the high-tech industry. He is the former Chief Financial Officer of Global Investment Holdings (ticker: 3701) and has previously held senior leadership positions across several major corporate groups, including Compal, VIA Technologies, and Foxconn. His professional expertise covers corporate finance, investment management, strategic planning, and business operations, with a proven track record in leading investment projects and corporate restructuring initiatives.Mr. Chu has also served as a board director or representative of numerous publicly listed companies, such as Go TrustID, Gorilla Technology, Yeastern Technology, and GCT Semiconductor (later merged into WIN Semiconductors). His corporate governance experience highlights his ability to bridge financial strategy with operational execution, guiding companies through critical growth and transformation stages.Prior to his CFO role, Mr. Chu was Vice President of Kuan Bao Technology (acting General Manager), Director of Investment at Tong Bao Optoelectronics, and Senior Manager at Compal Electronics. Earlier in his career, he worked as Investment Director at VIA Technologies, Assistant Vice President at Foxconn's PCB division, and Senior Electronic Research Analyst at Capital Securities.Mr. Chu received his MBA in Finance and Investment from Baruch College, City University of New York, and a BS in Electrical Engineering from National Chiao Tung University. His unique blend of engineering background and financial acumen allows him to navigate both the technical and strategic dimensions of investment and corporate management. - Yi An Chu，拥有广泛的金融、投资、科技背景，30多年专业经验横跨资本市场和高科技行业。他是Global Investment Holdings（股票代码：3701）的前任首席财务官，此前曾在几大企业集团担任高级领导职务，包括仁宝、威盛科技和富士康。他的专业专长涵盖企业融资、投资管理、战略规划和业务运营，在领导投资项目和企业重组举措方面拥有良好的业绩记录。Mr. Chu也曾担任过Go TrustID、Gorilla Technology、酵母科技、协鑫半导（后并入WIN Semiconductors）等多家上市公司的董事会董事或代表。他的公司治理经验凸显了他将财务战略与运营执行联系起来的能力，指导公司度过关键的增长和转型阶段。在担任CFO职务之前，Mr. Chu曾担任宽宝科技副总裁（代理总经理）、通宝光电投资总监、仁宝电子高级经理。在其职业生涯早期，他曾在威盛科技担任投资总监，在富士康PCB部门担任助理副总裁，在资本证券担任高级电子研究分析师。Mr. Chu在纽约市立大学巴鲁克学院获得金融与投资MBA学位，在国立交通大学获得电气工程学士学位。他独特地融合了工程背景和金融敏锐度，这使他能够驾驭投资和企业管理的技术和战略层面。
- Yi An Chu,with extensive backgrounds in finance, investment, and technology, has over 30 years of professional experience spanning the capital markets and the high-tech industry. He is the former Chief Financial Officer of Global Investment Holdings (ticker: 3701) and has previously held senior leadership positions across several major corporate groups, including Compal, VIA Technologies, and Foxconn. His professional expertise covers corporate finance, investment management, strategic planning, and business operations, with a proven track record in leading investment projects and corporate restructuring initiatives.Mr. Chu has also served as a board director or representative of numerous publicly listed companies, such as Go TrustID, Gorilla Technology, Yeastern Technology, and GCT Semiconductor (later merged into WIN Semiconductors). His corporate governance experience highlights his ability to bridge financial strategy with operational execution, guiding companies through critical growth and transformation stages.Prior to his CFO role, Mr. Chu was Vice President of Kuan Bao Technology (acting General Manager), Director of Investment at Tong Bao Optoelectronics, and Senior Manager at Compal Electronics. Earlier in his career, he worked as Investment Director at VIA Technologies, Assistant Vice President at Foxconn's PCB division, and Senior Electronic Research Analyst at Capital Securities.Mr. Chu received his MBA in Finance and Investment from Baruch College, City University of New York, and a BS in Electrical Engineering from National Chiao Tung University. His unique blend of engineering background and financial acumen allows him to navigate both the technical and strategic dimensions of investment and corporate management.
- Chen Huan Jan
-
Chen Huan Jan，是一位经验丰富的学术和商业领袖，其杰出的职业生涯跨越了三十多年，跨越了教育、国际商业外交和企业战略。Dr. Jan是Jan Elite International Co.，Ltd.的总裁和首席顾问，Gemtek Technology的独立董事和SelectFlorida的顾问。他在路易斯安那大学拉法叶分校获得数学博士学位，曾担任西佛罗里达大学客座助理教授、国立屏东大学副教授，在那里他创立了与美国在台协会（AIT）组织的台湾-美国商业论坛，以促进国际协作。在学术界之外，Dr. Jan一直深入加强台美关系，曾担任高雄美国商会理事。他获得多项荣誉，包括获得美国在台协会、美国商务部、美国爱达荷州政府的认可。
Chen Huan Jan,is a seasoned academic and business leader whose distinguished career spans over three decades across education, international business diplomacy, and corporate strategy.Dr. Jan is the president and chief consultant of Jan Elite International Co., Ltd., independent director of Gemtek Technology and a consultant of SelectFlorida. He earned his Ph.D. in Mathematics from the University of Louisiana at Lafayette and served as a visiting assistant professor at the University of West Florida, an associate professor at National Pingtung University, where he founded the Taiwan-U.S Commercial Forum organized with American Institute in Taiwan (AIT) to promote international collaboration. Beyond academia, Dr. Jan has been deeply engaged in strengthening Taiwan-U.S. relations and had served as Governor of the American Chamber of Commerce in Kaohsiung. He has received multiple honors, including recognition from the American Institute in Taiwan, the U.S. Department of Commerce, and U.S. Idaho state government. - Chen Huan Jan，是一位经验丰富的学术和商业领袖，其杰出的职业生涯跨越了三十多年，跨越了教育、国际商业外交和企业战略。Dr. Jan是Jan Elite International Co.，Ltd.的总裁和首席顾问，Gemtek Technology的独立董事和SelectFlorida的顾问。他在路易斯安那大学拉法叶分校获得数学博士学位，曾担任西佛罗里达大学客座助理教授、国立屏东大学副教授，在那里他创立了与美国在台协会（AIT）组织的台湾-美国商业论坛，以促进国际协作。在学术界之外，Dr. Jan一直深入加强台美关系，曾担任高雄美国商会理事。他获得多项荣誉，包括获得美国在台协会、美国商务部、美国爱达荷州政府的认可。
- Chen Huan Jan,is a seasoned academic and business leader whose distinguished career spans over three decades across education, international business diplomacy, and corporate strategy.Dr. Jan is the president and chief consultant of Jan Elite International Co., Ltd., independent director of Gemtek Technology and a consultant of SelectFlorida. He earned his Ph.D. in Mathematics from the University of Louisiana at Lafayette and served as a visiting assistant professor at the University of West Florida, an associate professor at National Pingtung University, where he founded the Taiwan-U.S Commercial Forum organized with American Institute in Taiwan (AIT) to promote international collaboration. Beyond academia, Dr. Jan has been deeply engaged in strengthening Taiwan-U.S. relations and had served as Governor of the American Chamber of Commerce in Kaohsiung. He has received multiple honors, including recognition from the American Institute in Taiwan, the U.S. Department of Commerce, and U.S. Idaho state government.
- Ya Chi Huang
-
Ya Chi Huang，为董事会带来了在台湾生物制药行业的生物技术投资、公司治理和研发方面的丰富经验。Dr. Huang目前在Maxpro Ventures担任助理副总裁，领导国内和国际投资活动。自2024年加入以来，她已成功完成对多家公司的投资，并管理其投资后运营。她还担任ANGENMED Therapeutics的董事。此前，Dr. Huang在Diamond Biofund（6901.TW）担任投资经理，在那里她独立完成了多项投资，并监督了Diamond所有投资组合公司的投后管理。她于2023年参与了Diamond Biofund在台湾证券交易所的IPO。在她职业生涯的早期，她曾在富邦证券投资服务公司担任研究部副经理，在那里她评估了台湾、中国大陆和香港超过150家未上市的生物科技公司，为富邦证券投行业务利润的大幅增长做出了贡献。Dr. Huang的科研背景包括在National Health研究所、生物技术发展中心和中央研究院担任研究职务。她关于EB病毒的博士研究发表在《血液》上，获得第12届TienTe Lee生物医学奖杰出论文奖。Dr. Huang拥有国立台湾大学医学院微生物学博士学位和国立中山大学生物科学硕士学位。
Ya Chi Huang,brings to the Board extensive experience in biotechnology investment, corporate governance, and research and development across Taiwan's biopharmaceutical industry.Dr. Huang currently serves as Assistant Vice President at Maxpro Ventures, where she leads domestic and international investment activities. Since joining in 2024, she has successfully completed investments in multiple companies and manages their post-investment operations. She also serves as a director of AngenMed Therapeutics.Previously, Dr. Huang served as Investment Manager at Diamond Biofund (6901.TW), where she independently completed multiple investments and oversaw post-investment management for all of Diamond's portfolio companies. She participated in Diamond Biofund's IPO on the Taiwan Stock Exchange in 2023. Earlier in her career, she was Deputy Manager in the Research Department at Fubon Securities Investment Services, where she evaluated over 150 unlisted biotech companies in Taiwan, China, and Hong Kong, and contributed to a significant increase in Fubon Securities' investment banking profits.Dr. Huang's scientific background includes research positions at the National Health Research Institutes, Development Center for Biotechnology, and Academia Sinica. Her doctoral research on Epstein-Barr virus was published in Blood and received the Distinguished Thesis Prize in the 12th TienTe Lee Biomedical Award.Dr. Huang holds a Ph.D. in Microbiology from National Taiwan University College of Medicine and an M.S. in Biological Sciences from National Sun Yat-sen University. - Ya Chi Huang，为董事会带来了在台湾生物制药行业的生物技术投资、公司治理和研发方面的丰富经验。Dr. Huang目前在Maxpro Ventures担任助理副总裁，领导国内和国际投资活动。自2024年加入以来，她已成功完成对多家公司的投资，并管理其投资后运营。她还担任ANGENMED Therapeutics的董事。此前，Dr. Huang在Diamond Biofund（6901.TW）担任投资经理，在那里她独立完成了多项投资，并监督了Diamond所有投资组合公司的投后管理。她于2023年参与了Diamond Biofund在台湾证券交易所的IPO。在她职业生涯的早期，她曾在富邦证券投资服务公司担任研究部副经理，在那里她评估了台湾、中国大陆和香港超过150家未上市的生物科技公司，为富邦证券投行业务利润的大幅增长做出了贡献。Dr. Huang的科研背景包括在National Health研究所、生物技术发展中心和中央研究院担任研究职务。她关于EB病毒的博士研究发表在《血液》上，获得第12届TienTe Lee生物医学奖杰出论文奖。Dr. Huang拥有国立台湾大学医学院微生物学博士学位和国立中山大学生物科学硕士学位。
- Ya Chi Huang,brings to the Board extensive experience in biotechnology investment, corporate governance, and research and development across Taiwan's biopharmaceutical industry.Dr. Huang currently serves as Assistant Vice President at Maxpro Ventures, where she leads domestic and international investment activities. Since joining in 2024, she has successfully completed investments in multiple companies and manages their post-investment operations. She also serves as a director of AngenMed Therapeutics.Previously, Dr. Huang served as Investment Manager at Diamond Biofund (6901.TW), where she independently completed multiple investments and oversaw post-investment management for all of Diamond's portfolio companies. She participated in Diamond Biofund's IPO on the Taiwan Stock Exchange in 2023. Earlier in her career, she was Deputy Manager in the Research Department at Fubon Securities Investment Services, where she evaluated over 150 unlisted biotech companies in Taiwan, China, and Hong Kong, and contributed to a significant increase in Fubon Securities' investment banking profits.Dr. Huang's scientific background includes research positions at the National Health Research Institutes, Development Center for Biotechnology, and Academia Sinica. Her doctoral research on Epstein-Barr virus was published in Blood and received the Distinguished Thesis Prize in the 12th TienTe Lee Biomedical Award.Dr. Huang holds a Ph.D. in Microbiology from National Taiwan University College of Medicine and an M.S. in Biological Sciences from National Sun Yat-sen University.
高管简历
中英对照 | 中文 | 英文- Howard Chen
Howard Chen，是Gemtek科技有限公司的创始人和董事长，也是Polaris Pharmaceuticals，Inc.的前董事长兼首席执行官，目前担任Polaris执行董事。Mr. Chen拥有台湾国立清华大学物理学学士及电子工程硕士学位。他的职业生涯始于台积电（TSMC），从事半导体工艺和集成电路的研发工作。后来他创立了Gemtek科技，该公司自此成长为全球领先的专业无线宽带设备制造商之一，在国际市场拥有强大的影响力。为表彰他对科技行业的贡献，Mr. Chen于2010年获得国立清华大学杰出校友奖，并于2013年获得ERSO奖，这是台湾科技领域最负盛名的荣誉之一。2019年，北极星制药面临严重的财务危机，因为其许多临床试验仍不确定，同时成本和费用超出了公司的能力。在这段困难时期，Mr. Chen介入，果断出手，稳住了公司。在他的领导下，北极星进行了全面的战略重组，在他的管理团队的努力下，公司实现了令人瞩目的扭亏为盈，最终于2022年6月在台湾成功IPO。
Howard Chen,is the Founder and Chairman of Gemtek Technology Co., Ltd. and the Former Chairman and CEO of Polaris Pharmaceuticals, Inc., and currently serving as an Executive Director of Polaris.Mr. Chen holds a Bachelor of Physics and a Master of Electronics Engineering from National Tsing Hua University, Taiwan. He began his career at Taiwan Semiconductor Manufacturing Company (TSMC), where he was engaged in research and development of semiconductor processes and integrated circuits.He later founded Gemtek Technology, which has since grown into one of the world's leading manufacturers of professional wireless broadband equipment, with a strong presence in international markets. In recognition of his contributions to the technology industry, Mr. Chen received the Outstanding Alumni Award from National Tsing Hua University in 2010 and was honored with the ERSO Award in 2013, one of the most prestigious accolades in Taiwan's technology sector.In 2019, Polaris Pharmaceuticals faced a severe financial crisis, as many of its clinical trials remained uncertain while costs and expenses exceeded the company's capacity. During this difficult period, Mr. Chen stepped in and took decisive action to stabilize the company. Under his leadership, Polaris underwent a comprehensive strategic reorganization, and with the efforts of his management team, the company achieved a remarkable turnaround, culminating in a successful IPO in Taiwan in June 2022.- Howard Chen，是Gemtek科技有限公司的创始人和董事长，也是Polaris Pharmaceuticals，Inc.的前董事长兼首席执行官，目前担任Polaris执行董事。Mr. Chen拥有台湾国立清华大学物理学学士及电子工程硕士学位。他的职业生涯始于台积电（TSMC），从事半导体工艺和集成电路的研发工作。后来他创立了Gemtek科技，该公司自此成长为全球领先的专业无线宽带设备制造商之一，在国际市场拥有强大的影响力。为表彰他对科技行业的贡献，Mr. Chen于2010年获得国立清华大学杰出校友奖，并于2013年获得ERSO奖，这是台湾科技领域最负盛名的荣誉之一。2019年，北极星制药面临严重的财务危机，因为其许多临床试验仍不确定，同时成本和费用超出了公司的能力。在这段困难时期，Mr. Chen介入，果断出手，稳住了公司。在他的领导下，北极星进行了全面的战略重组，在他的管理团队的努力下，公司实现了令人瞩目的扭亏为盈，最终于2022年6月在台湾成功IPO。
- Howard Chen,is the Founder and Chairman of Gemtek Technology Co., Ltd. and the Former Chairman and CEO of Polaris Pharmaceuticals, Inc., and currently serving as an Executive Director of Polaris.Mr. Chen holds a Bachelor of Physics and a Master of Electronics Engineering from National Tsing Hua University, Taiwan. He began his career at Taiwan Semiconductor Manufacturing Company (TSMC), where he was engaged in research and development of semiconductor processes and integrated circuits.He later founded Gemtek Technology, which has since grown into one of the world's leading manufacturers of professional wireless broadband equipment, with a strong presence in international markets. In recognition of his contributions to the technology industry, Mr. Chen received the Outstanding Alumni Award from National Tsing Hua University in 2010 and was honored with the ERSO Award in 2013, one of the most prestigious accolades in Taiwan's technology sector.In 2019, Polaris Pharmaceuticals faced a severe financial crisis, as many of its clinical trials remained uncertain while costs and expenses exceeded the company's capacity. During this difficult period, Mr. Chen stepped in and took decisive action to stabilize the company. Under his leadership, Polaris underwent a comprehensive strategic reorganization, and with the efforts of his management team, the company achieved a remarkable turnaround, culminating in a successful IPO in Taiwan in June 2022.
- Peter Lin
Peter Lin，是一位经验丰富的企业高管和投资者，拥有跨越生物技术、金融和私募股权的杰出职业生涯。他曾在Tanvex Biopharma、Tanvex CDMO、Tanvex Biopharma USA和台湾Tanvex Biologic Corporation担任重要领导职务，负责监督全球实体的财务战略、资本运营和公司治理。在加入Tanvex之前，Peter曾担任Theragent的首席财务官，Theragent是一家专注于基因和细胞治疗的开创性CDMO，在那里他帮助塑造了一家先进治疗领域高增长初创公司的财务基础。Peter的职业生涯也深深扎根于金融行业。作为精品私募股权公司Solarium Capital的负责人和投资经理，他领导了包括科技、食品和饮料以及房地产在内的多个领域的收购和股权投资。在他职业生涯的早期，在获得MBA学位后，Peter加入了WesCorp，担任投资研究经理，在那里他领导了一个信用研究团队，管理着320亿美元的固定收益投资组合——全球最大的结构性信贷投资组合之一。他的团队对美国和国际结构性金融工具进行了深入分析，包括MBS、ABS、CDO和公司债务证券。除了担任执行职务外，Peter还在多家公司的董事会任职，这些公司涵盖生物技术、医疗设备、媒体、出版和房地产私募股权投资企业。他拥有加州大学伯克利分校工商管理学士学位、克莱蒙特研究生大学信息系统硕士学位、南加州大学MBA学位。他还是特许另类投资分析师（CAIA）特许持有人，强调了他在另类投资和全球资本市场方面的专业知识。
Peter Lin,is a seasoned corporate executive and investor with a distinguished career spanning biotechnology, finance, and private equity. He has held key leadership roles as Chief Financial Officer at Tanvex Biopharma, Tanvex CDMO, Tanvex Biopharma USA, and Tanvex Biologic Corporation in Taiwan, where he oversaw financial strategy, capital operations, and corporate governance across global entities. Prior to Tanvex, Peter served as CFO of Theragent, a pioneering CDMO specializing in gene and cell therapy, where he helped shape the financial foundation of a high-growth startup in the advanced therapeutics space.Peter's career is also deeply rooted in the financial industry. As a principal and investment manager at Solarium Capital, a boutique private equity firm, he led acquisitions and equity investments across diverse sectors including technology, food and beverage, and real estate. Earlier in his career, after earning his MBA, Peter joined WesCorp as an investment research manager, where he directed a credit research team managing a $32 billion fixed-income portfolio—one of the largest structured credit portfolios globally. His team conducted in-depth analysis of U.S. and international structured finance instruments, including MBS, ABS, CDOs, and corporate debt securities.In addition to his executive roles, Peter serves on the boards of multiple companies spanning biotechnology, medical devices, media, publishing, and real estate private equity ventures. He holds a bachelor's degree in Business Administration from the University of California, Berkeley, a master's degree in Information Systems from Claremont Graduate University, and an MBA from the University of Southern California. He is also a Chartered Alternative Investment Analyst (CAIA) charterholder, underscoring his expertise in alternative investments and global capital markets.- Peter Lin，是一位经验丰富的企业高管和投资者，拥有跨越生物技术、金融和私募股权的杰出职业生涯。他曾在Tanvex Biopharma、Tanvex CDMO、Tanvex Biopharma USA和台湾Tanvex Biologic Corporation担任重要领导职务，负责监督全球实体的财务战略、资本运营和公司治理。在加入Tanvex之前，Peter曾担任Theragent的首席财务官，Theragent是一家专注于基因和细胞治疗的开创性CDMO，在那里他帮助塑造了一家先进治疗领域高增长初创公司的财务基础。Peter的职业生涯也深深扎根于金融行业。作为精品私募股权公司Solarium Capital的负责人和投资经理，他领导了包括科技、食品和饮料以及房地产在内的多个领域的收购和股权投资。在他职业生涯的早期，在获得MBA学位后，Peter加入了WesCorp，担任投资研究经理，在那里他领导了一个信用研究团队，管理着320亿美元的固定收益投资组合——全球最大的结构性信贷投资组合之一。他的团队对美国和国际结构性金融工具进行了深入分析，包括MBS、ABS、CDO和公司债务证券。除了担任执行职务外，Peter还在多家公司的董事会任职，这些公司涵盖生物技术、医疗设备、媒体、出版和房地产私募股权投资企业。他拥有加州大学伯克利分校工商管理学士学位、克莱蒙特研究生大学信息系统硕士学位、南加州大学MBA学位。他还是特许另类投资分析师（CAIA）特许持有人，强调了他在另类投资和全球资本市场方面的专业知识。
- Peter Lin,is a seasoned corporate executive and investor with a distinguished career spanning biotechnology, finance, and private equity. He has held key leadership roles as Chief Financial Officer at Tanvex Biopharma, Tanvex CDMO, Tanvex Biopharma USA, and Tanvex Biologic Corporation in Taiwan, where he oversaw financial strategy, capital operations, and corporate governance across global entities. Prior to Tanvex, Peter served as CFO of Theragent, a pioneering CDMO specializing in gene and cell therapy, where he helped shape the financial foundation of a high-growth startup in the advanced therapeutics space.Peter's career is also deeply rooted in the financial industry. As a principal and investment manager at Solarium Capital, a boutique private equity firm, he led acquisitions and equity investments across diverse sectors including technology, food and beverage, and real estate. Earlier in his career, after earning his MBA, Peter joined WesCorp as an investment research manager, where he directed a credit research team managing a $32 billion fixed-income portfolio—one of the largest structured credit portfolios globally. His team conducted in-depth analysis of U.S. and international structured finance instruments, including MBS, ABS, CDOs, and corporate debt securities.In addition to his executive roles, Peter serves on the boards of multiple companies spanning biotechnology, medical devices, media, publishing, and real estate private equity ventures. He holds a bachelor's degree in Business Administration from the University of California, Berkeley, a master's degree in Information Systems from Claremont Graduate University, and an MBA from the University of Southern California. He is also a Chartered Alternative Investment Analyst (CAIA) charterholder, underscoring his expertise in alternative investments and global capital markets.
- Yi Kuei Chen
Yi Kuei Chen，生物技术和风险投资背景，是Maxpro Ventures的联合创始人。Mr. Chen在资产管理方面的专业知识使他在美国和亚太地区成功执行了60多项私募股权投资交易。他过去的投资包括Acepodia、Syneurx、金斯瑞、JHL Biotech、Foresee、HEC Pharma和ACT Genomics Holdings等。在共同创立Maxpro Ventures之前，Mr. Chen是Integral Group的高级董事。他曾共同负责Integral的亚洲交易流程，管理其上海分公司，并担任过Generon Corporation、FusionVax，Inc.、BioLite，Inc.、Flora International Group Co.，Ltd.等多家投资组合公司的董事会成员。1999年至2012年，Mr. Chen曾在中环投资控股的投资部门担任多个高级管理职务。在此期间，他的成功投资包括Tanox和Biopure，仅举几例。2002年，Mr. Chen做过的一笔重大交易，就是新世纪信通科技收购SEEDNet。他还曾在多个公司董事会任职，如Concord Fund Company、Singfor Life Insurance Company、CTCI Corporation。Mr. Chen获得了雪城大学的MBA学位和明尼苏达大学的硕士学位。
Yi Kuei Chen,with backgrounds in biotechnology and venture capital, is a co-founder of Maxpro Ventures. Mr. Chen's professional expertise in asset management has led to his successful execution of more than 60 private equity investment transactions in the USA and the Asia-Pacific region. His past investments include Acepodia, SyneuRx, GenScript, JHL Biotech, Foresee, HEC Pharma, and ACT Genomics Holdings, amongst others.Prior to co-founding Maxpro Ventures, Mr. Chen was the Senior Director of Integral Group. He was jointly in charge of Integral's Asian transaction process, managed its Shanghai branch, and served as a board member of multiple portfolio companies such as Generon Corporation, FusionVax, Inc., BioLite, Inc., and Flora International Group Co., Ltd.. From 1999 to 2012, Mr. Chen held various senior management positions in the investment division at Central Investment Holdings. During that period, his successful investments included Tanox and Biopure, to name just a few. In 2002, a significant transaction that Mr. Chen had made was the acquisition of SEEDNet by New Century InfoComm Tech. He also served on several corporate boards, such as Concord Fund Company, Singfor Life Insurance Company, and CTCI Corporation.Mr. Chen received an MBA from Syracuse University and an MS from the University of Minnesota.- Yi Kuei Chen，生物技术和风险投资背景，是Maxpro Ventures的联合创始人。Mr. Chen在资产管理方面的专业知识使他在美国和亚太地区成功执行了60多项私募股权投资交易。他过去的投资包括Acepodia、Syneurx、金斯瑞、JHL Biotech、Foresee、HEC Pharma和ACT Genomics Holdings等。在共同创立Maxpro Ventures之前，Mr. Chen是Integral Group的高级董事。他曾共同负责Integral的亚洲交易流程，管理其上海分公司，并担任过Generon Corporation、FusionVax，Inc.、BioLite，Inc.、Flora International Group Co.，Ltd.等多家投资组合公司的董事会成员。1999年至2012年，Mr. Chen曾在中环投资控股的投资部门担任多个高级管理职务。在此期间，他的成功投资包括Tanox和Biopure，仅举几例。2002年，Mr. Chen做过的一笔重大交易，就是新世纪信通科技收购SEEDNet。他还曾在多个公司董事会任职，如Concord Fund Company、Singfor Life Insurance Company、CTCI Corporation。Mr. Chen获得了雪城大学的MBA学位和明尼苏达大学的硕士学位。
- Yi Kuei Chen,with backgrounds in biotechnology and venture capital, is a co-founder of Maxpro Ventures. Mr. Chen's professional expertise in asset management has led to his successful execution of more than 60 private equity investment transactions in the USA and the Asia-Pacific region. His past investments include Acepodia, SyneuRx, GenScript, JHL Biotech, Foresee, HEC Pharma, and ACT Genomics Holdings, amongst others.Prior to co-founding Maxpro Ventures, Mr. Chen was the Senior Director of Integral Group. He was jointly in charge of Integral's Asian transaction process, managed its Shanghai branch, and served as a board member of multiple portfolio companies such as Generon Corporation, FusionVax, Inc., BioLite, Inc., and Flora International Group Co., Ltd.. From 1999 to 2012, Mr. Chen held various senior management positions in the investment division at Central Investment Holdings. During that period, his successful investments included Tanox and Biopure, to name just a few. In 2002, a significant transaction that Mr. Chen had made was the acquisition of SEEDNet by New Century InfoComm Tech. He also served on several corporate boards, such as Concord Fund Company, Singfor Life Insurance Company, and CTCI Corporation.Mr. Chen received an MBA from Syracuse University and an MS from the University of Minnesota.